Name
Acute myeloid leukemia with minimal differentiation
ICD-O-2 Morphology
Effective
1995 - 2000
ICD-O-3 Morphology
Effective
2001 and later
Reportable
for cases diagnosed
1978 - 1991,
1995 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
See abstractor notes
Alternate Names
Acute myeloblastic leukemia
Acute myeloblastic leukemia, minimally differentiated
Acute myeloid leukemia, M0
Acute myeloid leukemia, minimal differentiation
FAB M0
Definition
Acute myeloid leukemia (AML) with minimal differentiation is an AML with no morphological or cytochemical evidence of myeloid differentiation. The myeloid nature of the blasts is demonstrated by immunological markers, which are essential for distinguishing this entity from lymphoblastic leukemia.
Definitive Diagnostic Methods
Genetic testing
Immunophenotyping
Genetics Data
Immunophenotyping
CD3- (no expression/negative)
CD13- (no expression/negative)
CD22- (no expression/negative)
CD33+ (expression/positive)
CD34+ (expression/positive)
CD38+ (expression/positive)
CD79a- (no expression/negative)
HLA-DR+ (expression/positive)
KIT (CD117)+ (expression/positive)
TdT+ (expression/positive)
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Transformations to
None
Transformations from
Same Primaries
Corresponding ICD-9 Codes
205.0 Acute myeloid leukemia
Corresponding ICD-10 Codes
C92.0 Acute myeloid leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C92.0 Acute myeloblastic leukemia (effective October 01, 2015)
Signs and Symptoms
Diagnostic Exams
CT (CAT) scan
Cytogenetic analysis
Immunophenotyping
Lumbar puncture
Peripheral blood smear
Physical exam and history
Reverse transcription-polymerase chain reaction test (RT-PCR)
Progression and Transformation
None
Epidemiology and Mortality
Age: most common in either infants or older adults
Incidence: <5% of all AML cases
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 156-157
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 156-157
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq